Jay Bradner, M.D.
@jaybradner
Physician-scientist making medicines with friends, memories with family. EVP R&D at Amgen
Big news today: Phase 3 trial results published in @NEJM highlight @Amgen innovation in small cell lung cancer (#SCLC). 🔗Read how #MyCompany is reshaping treatment options: bit.ly/3FsZ0SV
Delighted to see LLF580 (efimosfermin alfa) acquired by @GSK, an FGF21 biologic for MASH. Thanks to @BostonPharm for believing in this idea. Third NIBR-born spin-out to be acquired for approx $1 bn or more. endpts.com/gsk-to-pay-1-2…
RIP Downyflake. Have so many happy donut memories together.
The demolition of the Downyflake, one of the island’s most iconic restaurants, has begun. Pate Kennedy and Ron Oldham, who have owned the breakfast spot since 2014, are hoping to open at a new location in the near future. Lots are being cleared for a new residential-commercial…
Elegant use of dTAG to characterize the immediate consequences of ZFN143 loss on transcriptional targets.
ZNF143 is a transcriptional regulator of nuclear-encoded mitochondrial genes that acts independently of looping and CTCF dlvr.it/TH8pSN
Amazing trip back home to Chicago for #ASCO2025, with our deeply dedicated Amgen oncology colleagues and our fearless leader Dr. @jsoriamd. Feeling very hopeful about the future of cancer care, our industry continues to rise to the generational challenge.
A new Nature Medicine study sheds light on why KRAS G12C–mutated NSCLC patients respond differently to treatment. Insights from two trials reveal molecular features and early blood-based markers that may predict outcomes. Grateful to our @Amgen team involved. #MyCompany…
Hope you are having a restful and reflective Memorial Day weekend.
Grateful to join the Strategic Vision in Drug Discovery panel at #SDDS2025. At Amgen, we’re decoding disease at atomic resolution—advancing precision-based solutions grounded in deep human biology. Honored to share ideas with leaders pushing the boundaries of science.…
At the Stanford Drug Discovery Symposium 2025, Amgen CEO Bob Bradway and EVP, R&D @JayBradner shared a compelling vision for the future of medicine. Swipe through our carousel for an exclusive look at what they had to say.
At the @MilkenInstitute Global Conference panel, we discussed how AI, genetics & protein engineering are transforming drug discovery. From our research targeting Lp(a) to uncovering potentially protective mutations in obesity, we’re entering a new era of precision and…
New in Nature Metabolism: CNS GIPR and GLP-1R are both essential for weight loss response to a GIPR-Ab/GLP-1 peptide–antibody conjugate in mice—and this signaling happens through brain regions that reach outside the blood–brain barrier. This provides a new perspective on central…
Today, @NatMetabolism published new preclinical research in mice around blocking GIPR and activating GLP-1R. 🧬🔬 This study was led by @DanielJDrucker, Endocrinologist and Professor at @UofT, and Murielle Véniant-Ellison, Scientific VP at Amgen leading #obesity research. 🔗…
This #DNADay, we’re celebrating DNA as a tool for innovation. Our DEL platform uses DNA barcoding to screen billions of molecules in parallel, accelerating discovery of small-molecule therapies targeting even the most elusive biology. #MyCompany
Our DNA-Encoded Library (DEL) platform 🧬 is accelerating drug discovery by rapidly identifying molecules that have the potential to become therapies. This #DNADay, discover how we’re using DNA to advance therapeutics for those in need 🔗: amgen.ly/3EpGvON
Tumor infiltrating clonal hematopoiesis associated with poor outcomes in solid tumors. Wonder if this is how IL1B inhibition seemed to improve survival from cancer in CANTOS… nejm.org/doi/full/10.10…
Can you get too much of a good thing? Turns out ovarian cancer cells recurrently delete BRD4 regulatory elements to mute expression. So cool, even better from close friends. cell.com/cell-genomics/…
These results show exciting clinical benefit & represent an important advance in #SCLC care for people in desperate need of more effective treatment options. Looking forward to sharing these findings with the scientific community as we strive to bring @Amgen’s immunotherapy to…
SCLC #NEWS: Positive results from global Phase 3 trial show substantial survival improvement over chemotherapy in the second line. #SCLC is an aggressive cancer with high unmet need. 🔗 amgen.ly/4jy1IoG $AMGN
Wonderful to be among the @TheMarkFdn leadership and community in NYC, taking vital signs and exchanging perspectives on progress in cancer therapy.
Great to hear insights from @jaybradner in conversation with Ross Levine, chair of @MSKCancerCenter, on how academic & industry researchers can cooperate in translational research and drug discovery. #CancerInnovation #CancerResearch #MarkSymposium
Another terrific outcome for a NIBR-born medicine. Congratulations to Rene Hersperger, Christian Bruns and all who worked to develop this gorgeous little electrophile.
In two trials involving patients with chronic spontaneous urticaria, remibrutinib led to significantly greater reductions than placebo in itching and hives at week 12. Full results of the REMIX-1 and REMIX-2 trials: nej.md/41uQD07
Metastatic colorectal cancer is a difficult illness and targeted therapy has been elusive. Today brings new hope. Read about today’s landmark @US_FDAapproval for patients with previously treated KRAS G12C-mutated disease👇#MyCompany
The @US_FDA approved Amgen’s targeted combination therapy for the treatment of adult patients with chemorefractory KRAS G12C-mutated #mCRC. 🔗 Press release: amgen.ly/3DSN5fR $AMGN
Terrific discussion of core strategy, bleeding edge technology and ideal partnerships with @drcwestphal and @StanfordMed Dean Lloyd Minor @LongwoodFund JPM25.
A fantastic and fun discussion with @jaybradner @Amgen and @StanfordMed Dean Lloyd Minor led by @drcwestphal @longwoodfund #longwoodhealthcareleaders #SanFranciscoCEO #JPM25
Ready, set, degrade! So proud to share our work in @jclinicalinvest, establishing a versatile approach for creating transgenic dTAG mice to degrade oncoproteins. We showcase that KRAS G12V degradation triggers antitumor immunity in lung cancer. Link: jci.org/articles/view/… 🧵
Looking forward to JPM25 and time with these bioluminaries.
Join Peter Marks, @StanfordMed Dean, CEOs/R&D heads of @Amgen, @BayerPharma, @bmsnews, Merck Research Laboratories, @Novartis, @Roche @genentech & more the weekend prior to #JPM2025. See more: conta.cc/3VGvk9M